Amyloid diseases result in progressive conditions in which the healthy function of cells, tissues, and organs is disrupted by abnormal deposits of amyloid fibrils. Amyloid fibrils form when the body's normal proteins unravel and expose adhesive regions that cause the proteins to stick together, a process known as aggregation. The proteins attach to each other in regular patterns producing the repeating rope-like structures of amyloid fibrils. Over 20 different proteins are known to form amyloid fibrils in the body in over 50 diseases such as Alzheimer's, cardiomyopathy, diabetes and certain cancers.
ADRx technology: ADvantage Platform
ADRx was founded to develop and commercialize novel therapies that prevent the abnormal aggregation of proteins that cause amyloid diseases. Drug discovery at ADRx includes multiple strategies that fit together like puzzle pieces to form a proprietary universal platform for developing novel inhibitors of protein aggregation. The ADvantage platform begins with a detailed structural picture of each target protein or peptide and uses both computational and empirical screening tools to design molecules (antibodies, peptides, and small molecules) that prevent the growth of aggregates. The best designs are refined over multiple iterations of screening and are further tested in cellular and animal models of aggregation and disease.